EFFICACY AND TOLERANCE OF ORAL DIPYRONE VERSUS ORAL MORPHINE FOR CANCER PAIN

被引:49
|
作者
RODRIGUEZ, M
BARUTELL, C
RULL, M
GALVEZ, R
PALLARES, J
VIDAL, F
ALIAGA, L
MORENO, J
PUERTA, J
ORTIZ, P
机构
[1] EUROPHARMA SA, E-28020 MADRID, SPAIN
[2] HOSP CARLOS HAYA, MALAGA, SPAIN
[3] HOSP GEN VALLE HEBRON, BARCELONA, SPAIN
[4] HOSP SAN JUAN, REUS, SPAIN
[5] HOSP VIRGEN NIEVES, GRANADA, SPAIN
[6] HOSP LA FE, E-46009 VALENCIA, SPAIN
[7] HOSP GERMANS TRIAS & PUJOL, BADALONA, SPAIN
[8] HOSP SANTA CRUZ & SAN PABLO, BARCELONA, SPAIN
关键词
DIPYRONE; MORPHINE; ANALGESIA; EFFICACY; TOLERANCE; CANCER PAIN;
D O I
10.1016/0959-8049(94)90524-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a double-blind, randomised and parallel clinical trial, two oral doses of dipyrone (1 and 2 g) administered every 8 h were compared with 10 mg of oral morphine given every 4 h for the relief of chronic cancer pain. A total of 121 patients with cancer pain without gastric involvement participated in a 7-day treatment course and were allocated to receive either dipyrone 1 g (n = 41), dipyrone 2 g (n = 38) or morphine (n = 42). Drug efficacy was analysed according to the degree of pain relief using a 100-mm visual analogue scale, and the number of patients who decided to increase the dose of the analgesic drug on day 4. The analgesic effect of dipyrone, 2 g every 8 h, was similar to that of morphine. The efficacy of both schedules was significantly greater than that of dipyrone, 1 g every 8 h. Dipyrone at either 1 or 2 g doses tended to be better tolerated than morphine, although the differences were not statistically significant.
引用
收藏
页码:584 / 587
页数:4
相关论文
共 50 条
  • [41] Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain
    Pantouli, Fani
    Grim, Travis W.
    Schmid, Cullen L.
    Acevedo-Canabal, Agnes
    Kennedy, Nicole M.
    Cameron, Michael D.
    Bannister, Thomas D.
    Bohn, Laura M.
    NEUROPHARMACOLOGY, 2021, 185
  • [42] Efficacy of Low-Dose Oral Liquid Morphine for Elderly Patients with Chronic Non-Cancer Pain: Retrospective Chart Review
    Lee J.
    Lakha S.F.
    Mailis A.
    Drugs - Real World Outcomes, 2015, 2 (4) : 369 - 376
  • [43] The effects of oral morphine in "titration phase" of carcinoma pain treatment
    Ljuca, Dzenita
    Husic, Samir
    HEALTHMED, 2010, 4 (02): : 434 - 440
  • [44] Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain
    Tassain, V
    Attal, N
    Fletcher, D
    Brasseur, L
    Dégieux, P
    Chauvin, M
    Bouhassira, D
    PAIN, 2003, 104 (1-2) : 389 - 400
  • [45] The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain
    Lasheen, Wael
    Walsh, Declan
    Mahmoud, Fade
    Sarhill, Nabeel
    Rivera, Nilo
    Davis, Mellar
    Lagman, Ruth
    Legrand, Susan
    PALLIATIVE MEDICINE, 2010, 24 (01) : 9 - 16
  • [46] Oral papaverine prevents morphine-induced constipation without interfering with analgesia achieved with oral morphine
    Jurna, I
    Jurna, K
    Baldauf, J
    Zenz, M
    SCHMERZ, 1996, 10 (01): : 27 - 35
  • [47] Investigations on efficacy and tolerance of a subcutaneous and subsequent oral treatment of meloxicam in dogs
    Nautrup, BP
    Justus, C
    Philipp, H
    Kleemann, R
    TIERAERZTLICHE UMSCHAU, 1999, 54 (04) : 199 - +
  • [48] Atorvastatin calcium tablets effectively alleviated the morphine tolerance in the management of cancer pain
    Quan, LF.
    Fan, J.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2024, 22 (02): : 499 - 502
  • [49] IS DISEASE PROGRESSION THE MAJOR FACTOR IN MORPHINE-TOLERANCE IN CANCER PAIN TREATMENT
    COLLIN, E
    POULAIN, P
    GAUVAINPIQUARD, A
    PETIT, G
    PICHARDLEANDRI, E
    PAIN, 1993, 55 (03) : 319 - 326
  • [50] Influence of oral buprenorphine, oral naltrexone or morphine on the effects of laparotomy in the rat
    Liles, JH
    Flecknell, PA
    Roughan, J
    Cruz-Madorran, I
    LABORATORY ANIMALS, 1998, 32 (02) : 149 - 161